Any biotech nerds want to weigh in on the accuracy of this comparison?
Thx,
Dreamer
1 Like
XBI is doing well. But my shares are on loan to a short seller. Some must see potential for a correction.
PRME being destroyed past week in sympathy drops tied a lot to NTLA who apparently had a death in a liver study or something. They have ER and KOL day next week so may bounce, but who knows w biotech.
While Esperion mgmt is shady and suspect at times, at least that business seems easy to measure w actual sales.
Once i move on from Esperion, probably not touching biotech for a while.
AI/data and gene editing likely do lead to transformational change. Just dont know which stock ultimately benefits.
Dreamer
1 Like